- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05802342
A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer
March 27, 2023 updated by: Qilu Pharmaceutical Co., Ltd.
a Multicenter, Randomized, Double-blind Phase II Trial To Evaluate Monosialate Tetrahexose-ganglioside Sodium Injection (GM1) for Prevention of Peripheral Neuropathy in Patients With Breast Cancer Induced by Albumin-bound Paclitaxel Regimen Adjuvant/Neoadjuvant Therapy
This randomized, double-blind, multicenter, placebo-controlled Phase II trial was designed to investigate the efficacy and safety of GM1 in the prevention of peripheral neuropathy caused by albumin-bound paclitaxel regimen in breast cancer patients.This study was randomly divided into 3 groups at 1:1:1 with 50 subjects in each group Subjects received study treatment until the end of treatment for a total of 4/6 cycles.
The treatment period was GM1/ placebo combined with albumin-bound paclitaxel therapy.
GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-bound paclitaxel was administered starting on day D1, with a total of 4/6 cycles.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
150
Phase
- Phase 2
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Fully understand the content of the experiment and voluntarily sign the informed consent;
- Age from 18 to 75 years old (including both ends);
- Breast cancer patients who provide definitive histological and/or cytological diagnosis of breast cancer and are proposing adjuvant/neoadjuvant therapy with the albumin-paclitaxel regimen;
- ECOG score 0~1;
- The organ function level must meet the requirements
- Subjects (both male and female) agreed to use effective contraception from the time of signing the informed consent to 30 days after the last use of the study drug. Female subjects of childbearing age cannot be pregnant or lactating.
- Patients can accurately record or express the occurrence and severity of neurotoxicity in questionnaires;
- After enrollment, patients should not receive other treatments or care that might prevent or treat neurotoxic adverse events
Exclusion Criteria:
- Presence of grade 1 peripheral neurotoxicity (CTCAE≥1) or symptoms of peripheral neuropathy (FACT/GOG-Ntx≥1)
- There are risk factors for peripheral neuropathy (except peripheral neuropathy caused by chemotherapy),Including but not limited to: diabetic peripheral neuropathy; Peripheral vascular disease; Folic acid, B12 vitamin deficiency; Postoperative neuropathy; Post-traumatic neuropathy; Peripheral neuroinflammatory lesions; Peripheral neuropathy caused by tumor compression and infiltration; Other researchers believe that can cause limb pain, numbness, paresthesia, dysfunction of the skin, muscle, vascular diseases;
- Cardiovascular and cerebrovascular diseases, including but not limited to: Myocardial infarction (within 6 months before signing the informed consent), unstable angina, high risk of uncontrollable arrhythmia, coronary artery bypass grafting, cerebrovascular accident (within 6 months before signing the informed consent), congestive heart failure (cardiac function grade III-Ⅳ), pulmonary embolism, deep vein thrombosis, and other cardiovascular and cerebrovascular systems deemed unsuitable for inclusion by the investigator General disease;
- Uncontrolled hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg) after optimal treatment with antihypertensive drugs; Patients with blood pressure deemed unsuitable for clinical trials by the investigator;
- Diabetic patients with HBA1c ≥9.0%;
- Active bacterial, fungal, or viral infections that require systematic treatment within one week prior to initial administration; Infectious diarrhea occurred within 4 weeks prior to initial administration;
- History of inherited abnormal glucose and lipid metabolism (ganglioside accumulation disease, such as familial amaurosis, retinal degeneration) or autoimmune disease;
- Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); Syphilis antibody positive;
- Active hepatitis B (HBsAg positive with HBV-DNA > 500 IU/ml or lower limit of Center detection [only when lower limit of Center detection is higher than 500 IU/ml]), active hepatitis C (patients with HCV antibody positive but HCV-RNA < lower limit of Center detection are admitted);
- Known allergy to ganglioside drugs or any excipient component of such products; Or to treat an allergy to a drug or any excipient component of such product;
- Patients who, in the judgment of the investigator, may increase the risk associated with the study, may interfere with the interpretation of the study results, or may be deemed unsuitable for inclusion by the investigator and/or sponsor.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
GM1 (100 mg) + albumin paclitaxel
|
The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6.
The treatment period was GM1/ placebo with albumin-paclitaxel.
GM1/ placebo was administered every 2 weeks /3 weeks.
GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
GM1/ placebo was administered every 2 weeks /3 weeks.
GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
|
Experimental: B
GM1 (400 mg) + albumin paclitaxel
|
The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6.
The treatment period was GM1/ placebo with albumin-paclitaxel.
GM1/ placebo was administered every 2 weeks /3 weeks.
GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
GM1/ placebo was administered every 2 weeks /3 weeks.
GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
|
Placebo Comparator: C
placebo + albumin paclitaxel
|
The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6.
The treatment period was GM1/ placebo with albumin-paclitaxel.
GM1/ placebo was administered every 2 weeks /3 weeks.
GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
GM1/ placebo was administered every 2 weeks /3 weeks.
GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Grade ≥2 neurotoxicity (CTCAE)
Time Frame: C4D3
|
C4D3
|
The difference between the FACT/GOG-Ntx score and the baseline score
Time Frame: C4D3
|
C4D3
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of peripheral neurotoxicity during cycles 1 to 6 and follow-up
Time Frame: 12 month
|
12 month
|
Change in FACT/GOG-Ntx scores from baseline during 1-6 cycles and follow-up
Time Frame: 12 month
|
12 month
|
Change in CIPN20 score from baseline after 1-6 cycles and follow-up
Time Frame: 12 month
|
12 month
|
incidence of adverse events
Time Frame: 12 month
|
12 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 20, 2023
Primary Completion (Anticipated)
December 31, 2024
Study Completion (Anticipated)
December 31, 2025
Study Registration Dates
First Submitted
March 27, 2023
First Submitted That Met QC Criteria
March 27, 2023
First Posted (Actual)
April 6, 2023
Study Record Updates
Last Update Posted (Actual)
April 6, 2023
Last Update Submitted That Met QC Criteria
March 27, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GM1-CIPN-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients
-
Hadassah Medical OrganizationCompletedTo Evaluate Effectiveness of the Gait Trainer in Increasing the Functionality and Spatiotemporal Parameters of Gait of 4 Patients.Israel
-
Tianjin University of Traditional Chinese MedicineNational Basic Research Program, ChinaCompletedto Evaluate the Effectiveness of Acupucnture in the Management of Chemotherapy-induced Nausea and VomitingChina
-
Sheba Medical CenterUnknownTo Demonstrate That the Closed Loop System Can be Used Safely Over a Few Consecutive Days. | To Assess Effectiveness in Maintaining Patients' Glucose Levels in the Target Range of 70 to 180 mg/dl, Measured by Blood Glucose Sensor. | To Evaluate the User Experience With a Closed Loop...Israel
-
Shen LinNot yet recruitingTo Evaluate the Safety and Effectiveness of Immunotherapy During the Perioperative Treatment Stage in MSI-H Gastrointestinal CancerChina
-
Shanghai General Hospital, Shanghai Jiao Tong University...Not yet recruitingTo Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)
-
Institut fuer FrauengesundheitNovartis; ClinSolUnknownis to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.Germany
-
Istanbul University - Cerrahpasa (IUC)UnknownThe Aim of Our Study is to Prospectively Evaluate the Optic Neuropathy in Nasopharynx Cancer PatientsTurkey
-
Finnish Breast Cancer GroupCompletedImprove Quality of Life | Prevent Osteoporosis and Osteoporotic Fractures | Improve Weight Control, and Muscular and Cardiovascular Fitness | Help the Patients to Return to Working Life | Reduce the Risk of Breast Cancer Recurrence | Reduce All-cause Mortality in Patients With Primary Breast...Finland
Clinical Trials on Monosialotetrahexose ganglioside sodium injection
-
Sun Yat-sen UniversityRecruitingBreast Cancer | Cognitive Impairment | Brain Metastases | Radiotherapy Side Effect | Gangliosidosis, GM1China
-
Tongji HospitalRecruiting
-
Beijing Tiantan HospitalNot yet recruitingEdema Brain
-
National Institute of Neurological Disorders and...Completed
-
Livzon Pharmaceutical Group Inc.UnknownCarcinogenic FatigueChina
-
The Second Hospital of Hebei Medical UniversityUnknownCerebral Infarction | Cerebral EdemaChina
-
Southeast University, ChinaUnknown
-
PfizerCompletedMacular Edema | Retinal Disease | Diabetic MellitusJapan
-
Bausch & Lomb IncorporatedCompletedAge-Related Macular Degeneration | Diabetic Macular Edema | Retinal Vein OcclusionUnited States